Regulation of Zbp1 by miR-99b-5p in microglia controls the development of schizophrenia-like symptoms in mice

Lalit Kaurani1, Md Rezaul Islam2, Urs Heilbronner3

  • 1Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) Goettingen, 37077, Göttingen, Germany. lalit.kaurani@dzne.de.

The EMBO Journal
|March 26, 2024
PubMed

Insights

This study reveals a new microRNA-99b-5p pathway involving Z-DNA binding protein 1 (Zbp1) in microglia. Reduced miR-99b-5p levels in schizophrenia patients may drive disease pathology via this pathway.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Schizophrenia treatment primarily targets protein-coding genes, overlooking microRNAs.
  • MicroRNAs play crucial roles in gene regulation and cellular processes.

Purpose of the Study:

  • To investigate the role of microRNAs in schizophrenia pathogenesis.
  • To identify specific microRNAs dysregulated in schizophrenia patients.
  • To elucidate the molecular mechanisms underlying microRNA involvement.

Main Methods:

  • Analysis of microRNAome in blood and postmortem brain tissue from schizophrenia patients.
  • Induction of schizophrenia-like phenotypes in mice by manipulating miR-99b-5p levels.
  • Identification of Z-DNA binding protein 1 (Zbp1) as a direct target of miR-99b-5p.
  • Assessment of therapeutic potential using antisense oligonucleotides against Zbp1.

Main Results:

  • miR-99b-5p expression is significantly downregulated in the prefrontal cortex and blood of schizophrenia patients.
  • Reduced miR-99b-5p in mice induced schizophrenia-like behaviors and microglial inflammation linked to synaptic pruning.
  • Zbp1 was identified as a novel target of miR-99b-5p, mediating the inflammatory response in microglia.
  • Antisense oligonucleotides targeting Zbp1 alleviated pathological effects.

Conclusions:

  • A novel microglial pathway involving miR-99b-5p and Zbp1 contributes to schizophrenia pathogenesis.
  • This pathway represents a potential therapeutic target for schizophrenia treatment.